Inotek raises $19.3M

Inotek Pharmaceuticals has raised $19.3 million in a third round of financing. New investors included Hercules Technology Growth Capital, Meditor Capital Management, and Mitsubishi UFJ Capital. Inotek said the money will be used to support the first proof of efficacy data for three separate therapeutic programs. Inotek also plans on expanding its development team.

- see this release from Inotek

Related Articles:
Inotek inks $625M licensing deal on PARP. Report
Inotek closes second round with additional $10M. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.